Skip to main content
. 2009 Jan 7;296(3):F512–F520. doi: 10.1152/ajprenal.90629.2008

Fig. 9.

Fig. 9.

TLO formation is reduced and renal function is improved by neutralizing TGF-β antibody. A: kidney sections from WT mice treated with vehicle (V; PBS) and CnAα+/− mice treated with vehicle (PBS), nonspecific IgG, or TNA were examined and lymphocyte infiltration scores by blinded reviewers. Data shown are percentage of 6 WT and 10 CnAα+/− mice in each group that received a score <3 or ≥3. **P < 0.05, Fisher's exact test. B: serum was collected and BUN values were measured for WT and CnAα+/− mice treated with vehicle (PBS), IgG, or TNA. Data shown are means ± SE of 6 WT mice and 10 CnAα+/− mice per treatment group. *P < 0.05 ANOVA. C: serum osmolality was measured for WT and CnAα+/− mice treated with vehicle (PBS), IgG, or TNA. Data shown are means ± SE of 6 WT mice and 10 CnAα+/− mice per treatment group. *P < 0.05 ANOVA. D: lymphocyte infiltration was scored by 2 blinded reviewers in intestine, liver, and lung sections. Data shown are percentage of vehicle-treated, IgG-treated, and TNA-treated CnAα+/− mice that received a score of <3 or ≥3. *P < 0.05, χ2 analysis.